Novartis AG
SIX:NOVN
Intrinsic Value
The intrinsic value of one
NOVN
stock under the Base Case scenario is
80.15
CHF.
Compared to the current market price of 79.39 CHF,
Novartis AG
is
Undervalued by 1%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
NOVN Profitability Score
Profitability Due Diligence
Novartis AG's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Score
Novartis AG's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
NOVN Solvency Score
Solvency Due Diligence
Novartis AG's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Novartis AG's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Novartis AG
NOVN Capital Structure
Novartis AG
| Market Capitalization | 171B CHF | |
| Total Debt | 21.2B CHF | |
| Minority Interest | 78M CHF | |
| Preferred Equity | 0 CHF | |
| Cash and Equivalents | 8.7B CHF | |
| Short-Term Investments | 10.4B CHF | |
| Enterprise Value | 173B CHF | |
Wall St
Price Targets
NOVN Price Targets Summary
Novartis AG
According to Wall Street analysts, the average 1-year price target for
NOVN
is 91.5 CHF
with a low forecast of 70.7 CHF and a high forecast of 111.3 CHF.
Competitive Landscape
NOVN Competitors
Novartis AG
NOVN Suppliers & Customers
Novartis AG
Novartis AG has 114 key suppliers from 12 countries and 19 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.
Novartis AG has 45 key customers from 9 countries and 8 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.
Shareholder Return
NOVN Price
Novartis AG
| Average Annual Return | 4.32% |
| Standard Deviation of Annual Returns | 14.86% |
| Max Drawdown | -27% |
| Market Capitalization | 171B CHF |
| Shares Outstanding | 2 204 239 028 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Novartis AG
Country
Industry
Market Cap
Dividend Yield
Description
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 104,323 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Contact
IPO
Employees
Officers
The intrinsic value of one
NOVN
stock under the Base Case scenario is
80.15
CHF.
Compared to the current market price of 79.39 CHF, Novartis AG is Undervalued by 1%.
